Trial Profile

LOw-Dose Tolvaptan in Decompensated Heart Failure Patients with Severe Aortic Stenosis - LOHAS registry -

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolvaptan (Primary) ; Tolvaptan (Primary)
Indications Decompensated heart failure; Heart failure
Focus Therapeutic Use
Acronyms LOHAS

Most Recent Events

13 Sep 2020 Status changed from active, no longer recruiting to completed.
01 Sep 2020 Primary endpoint ( Daily and 4-days total of Urine volume and Fluid balance) has not been met as per results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
01 Sep 2020 Primary endpoint (Change of body weight between admission and day 4) has been met as per results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com